The Trump administration’s Most Favored Nation (MFN) initiative may be one of the most transformative — and hotly debated — drug pricing policies in recent history. As stakeholders across the health care continuum prepare for its potential effects, the first of a three-part webinar series offers timely and essential perspectives on how MFN could impact health care, including: 

• Who may benefit, who may lose out and what’s next for this policy strategy.  

• Pharma’s response, potential legal challenges and industry pricing strategy.  

• Its impact on innovation, global markets and the U.S. first-to-launch status.  

• Its impact on pharmacy benefit manager (PBM) contracts, rebate structures and distribution models.  

• Patient access implications. 

Event:  

“The Most Favored Nation Mandate: What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients” webinar  

Date/time:  

Wednesday, Sept. 10, 2025 at 6 p.m. CT (7 p.m. ET)  

Moderator:  

• Ned Milenkovich, PharmD, JD, chair of the health care practice at Much Shelist, P.C.  

Speakers:  

• George Van Antwerp, MBA, senior vice president of product innovation and strategic planning at Prime Therapeutics  

• Brian Corvino, principal and global market access practice leader at Deloitte 

• Neal Masia, Ph.D., co-founder and chief executive officer at EntityRisk, Inc.  

• Ali Pashazadeh, founder, chairman and chief executive officer at Treehill Partners  

Register for the event